BCAX logo

BCAX Bicara Therapeutics Inc. Common Stock

NASDAQ Global Market · Biotechnology · Healthcare

$8.44
-0.68 (-7.46%)

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works…

Market Cap: $560.31Mwww.bicara.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
4 mentions
—
60d
50
4 mentions
—
90d
50
4 mentions
—
news: 4

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 2Sell 1Strong Sell 0
Avg price target$28.29+235.2%
Low $8Median $31High $41
Current Consensus

Revenue

$0.00
$0.00
Mar 2023Sep 2026

Analyst Estimates

FY2025
$-2.52
$-2.57–$-2.45
9 analysts
FY2026
$-3.84
$-3.97–$-3.65
10 analysts
FY2027
$-4.07
$-4.61–$-3.31
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Claire Mazumdar Clemon
Sector
Healthcare
Industry
Biotechnology
Employees
103
Beta
-0.82
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
4.38
www.bicara.com